William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating on August 1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors that suggest Edwards Lifesciences is well-positioned for future growth despite recent regulatory challenges. The FTC’s decision to block the acquisition of JenaValve Technology does not alter the fundamental outlook for the company, as the acquisition was not factored into the current revenue model. This indicates that the company’s growth prospects remain intact without the deal.
Moreover, Edwards Lifesciences has raised its full-year EPS guidance, reflecting stronger-than-expected financial performance. The company is also poised to benefit from ongoing developments in its asymptomatic TAVR and TMTT segments, which are expected to drive revenue growth. These elements combined support the Buy rating, as the company is likely to maintain or accelerate its top-line growth in the coming years.
In another report released on August 1, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.